Drug Type Small molecule drug |
Synonyms ASTX-030 |
Target |
Mechanism CDA inhibitors(Cytidine deaminase inhibitors), DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H12N4O5 |
InChIKeyNMUSYJAQQFHJEW-KVTDHHQDSA-N |
CAS Registry320-67-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 3 | US | 21 May 2020 | |
Acute Myeloid Leukemia | Phase 3 | CA | 21 May 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | US | 21 May 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | CA | 21 May 2020 | |
Myelodysplastic Syndromes | Phase 3 | US | 21 May 2020 | |
Myelodysplastic Syndromes | Phase 3 | CA | 21 May 2020 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 3 | US | 21 May 2020 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 3 | CA | 21 May 2020 | |
Adult Acute Myeloblastic Leukemia | Phase 1 | US | 30 Jan 2022 |